Predictive Oncology Closes Registered Direct Offering

Core Viewpoint - Predictive Oncology Inc. has successfully closed a registered direct offering of 363,336 shares of common stock at a price of $1.50 per share, generating gross proceeds of approximately $545,004 before expenses [1][2]. Company Overview - Predictive Oncology is a leader in AI-driven drug discovery and biologics, utilizing its AI platform, PEDAL, which predicts with 92% accuracy the response of tumor samples to drug compounds [5]. - The company has a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive AI-based drug discovery solutions [5]. - Predictive Oncology is headquartered in Pittsburgh, PA [5]. Offering Details - The offering was conducted under a "shelf" registration statement declared effective by the SEC on May 21, 2024, and the final prospectus supplement was filed on February 19, 2025 [3]. - H.C. Wainwright & Co. acted as the exclusive placement agent for the offering [1].